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It is a great honour for me to take over as Editor-in-Chief from Dr
Robin Weiss.
Robin was the Director of the Institute for Cancer Research when
I was a research fellow and gave me excellent advice on training in
molecular biology. He has shown a clear vision in developing the
British Journal of Cancer into multidisciplinary journal with a
focus on research that aims to deliver benefits to cancer patients.
Under his leadership, the journal has become both more
selective and more broadly based. A new section has been
established specifically devoted to genetic approaches to the
aetiology and progression of cancer and the new understanding
that is developing from genomic studies. At the same time, these
approaches have influenced all sections of the journal, which is
now a natural home for well-planned rigorous studies, whether
clinical, therapeutic or designed to illuminate basic processes in
the disease, that are informed by the best of modern science. These
are exciting times.
This explosion of ideas in cancer biology and therapies brings a
pressing need for up-to-date overviews of new developments.
Robin encouraged the commissioning of a very successful ongoing
series of Minireviews in BJC designed to bring readers expert
opinions and insights from leaders in the field.
He has encouraged debate within the pages of BJC and has led it
through the earliest beginnings of web-based electronic publishing
to a position where the rapid schedules of ‘advanced on-line
publishing’ are bringing real benefits to the research community
and offer great promise to those engaged in delivering the best
care. I look forward to my own involvement in these develop-
ments.
Our understanding of the environmental and molecular causes
of cancer, diagnostic imaging, pathology and therapeutic ap-
proaches to cancer have changed markedly in the last decade.
These processes continue to develop at an accelerating rate,
providing a challenge to all those involved in cancer research and
therapy to keep up to date in their own and relevant fields, and to
produce high-quality research.
The publication strategy of BJC reflects these changes,
emphasising clinical translational research and preclinical inves-
tigations that are critical for new therapeutic approaches and drug
development.
Clinical research covers a broad remit. Potentially the greatest
gains in cancer survival, for the least cost, are informed by
epidemiology and will involve changes in lifestyle. However, what
determines individual responses to similar genetic or environ-
mental changes? With the advent of high-throughput molecular
analyses, as well as proteomics, the underlying mechanisms and
pathways of relevance to the population and the individual can be
investigated in a far more sophisticated way. Epidemiology has
been an area strongly supported by the BJC and this will continue
with alternate issues having an epidemiology section.
A major change in paradigm for cancer treatment has been to
try and fit the therapy in the individual to match the oncogenic
pathway in the cancer. Although recognised for nearly 30 years in
management of breast cancer with use of the oestrogen receptor to
select for hormonal therapy, it has only recently been applied in
other situations as the therapeutic agents targeting specific
pathways have become available. Herceptin and several anti-
body-targeted toxins and low molecular weight tyrosine kinase
inhibitors have made a major impact on survival from cancer.
Thus, defining molecular pathways in cancer particularly in
relationship to survival patterns of relapse and therapeutic response
will be a mission for publications in British Journal of Cancer.
New diagnostic approaches including imaging, the relationship
of imaging to tumour pathology and molecular mechanisms will be
an important area for drug development and clinical practice.
Gene array analyses and proteomics may provide the next
generation of diagnostic classification, which will need to be
related to therapeutic selection. Appropriate statistical analyses of
survival, interactions of multiple pathways, sufficient patient
numbers and duration of follow-up will be necessary to draw
reliable conclusions. We will thus be including guidelines in these
areas to help authors’ submissions. Genetics is at the interfaces of
cancer risk, diagnoses, outcome and therapeutic development and
will continue to be an important area for the BJC.
The development of new drugs has become much more
complex, highly regulated and expensive. With specific targets
for new agents, demonstration that the target has been appro-
priately modified, for example, inhibition of receptor signalling
either in the tumour or surrogate tissue is now an early decision
point in drug development. The integration of pharmacokinetics
with pharmacodynamic end points of the type described above is a
key design for rational development of therapy. The British Journal
of Cancer is keen to support publication of Phase I and II trials that
incorporate novel features and end points in their designs,
including imaging as well as surrogate end points or assays on
tumour biopsies.
Critical preclinical experiments are, of course, essential to even
reach the stage of Phase I trials, and there must be continued
evaluation of mechanisms of action of existing agents, how they
interact with each other and the new approaches. The British
Journal of Cancer supports ethically conducted research in
Experimental Therapeutics. More sophisticated models involving
gene knockouts, mutations or genetically engineered lines that
provide new models to assess therapeutics or mechanisms of
disease will be supported and provide an opportunity for
validating clinical end points. This section will be renamed
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Final adoption of a new therapy and the optimisation of existing
therapy depend on the outcome of randomised Phase III trials.
Methodology for their analysis continues to undergo development and
analysis of molecular pathways in the patient and tumour will almost
certainly contribute to understanding of who benefits most from
treatment. Ultimately, selection as is currently applied to antibody-
targeted therapy will be necessary to use combination single agents
appropriately in adjuvant therapy. Thus, the BJC supports Phase III
trials, particularly if factors relating to outcome can be defined.
We must not forget the impact of these treatments on patients’
quality of life and their agenda. The BJC continues to invite papers
in this area.
Journals have become more specialised, and there are specific
journals for every pathway or clinical situation described above. It
thus becomes increasingly important to have a journal that can
cover a breadth of cancer research relevant to translational
scientists and clinicians, in order to foster communication, the
generation of crossdisciplinary knowledge and ideas, to enable
investigators to keep up to date in areas in addition to their
specific focus. We therefore think the Minireviews designed to be
short, pithy and written by the scientists who did the research will
continue to be an important regular feature. They will address
basic molecular biology of translational relevance and the science
behind new therapeutic developments.
I hope therefore that the BJC will continue to flourish as a cross
and multidisciplinary journal, and that it will become the journal
of choice for translational cancer research.
AL Harris
Editor-in-Chief
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